𝗠𝗮𝗿𝗸 𝘆𝗼𝘂𝗿 𝗰𝗮𝗹𝗲𝗻𝗱𝗮𝗿: 𝗙𝗬𝟮𝟲 𝗤𝟭 𝗲𝗮𝗿𝗻𝗶𝗻𝗴𝘀 𝗰𝗮𝗹𝗹
Join us Monday, September 15, 2025, at 10:30am EST for an update on quarterly highlights fueling growth.
**𝗜𝗣𝗔 𝗮𝗻𝗱 𝗶𝘁𝘀 𝘀𝘂𝗯𝘀𝗶𝗱𝗶𝗮𝗿𝗶𝗲𝘀 𝗮𝗿𝗲 𝗻𝗼𝘄 𝘂𝗻𝗶𝗳𝗶𝗲𝗱 𝘂𝗻𝗱𝗲𝗿 𝗼𝗻𝗲 𝗯𝗿𝗮𝗻𝗱: 𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸™** 𝗩𝗶𝘀𝗶𝘁: 𝗺𝗶𝗻𝗱𝘄𝗮𝗹𝗸𝗔𝗜.𝗰𝗼𝗺
𝗣𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝗻𝘁 𝗗𝗶𝗮𝗹-𝗜𝗻 𝗗𝗲𝘁𝗮𝗶𝗹𝘀
Joining by Phone
USA / International Toll +1 (646) 307-1963
USA - Toll-Free (800) 715-9871
Canada - Toronto (647) 932-3411
Canada - Toll-Free (800) 715-9871
Participants call one of the allocated dial-in numbers and advise the Operator of either the Conference ID 3224490 or Conference Name.
𝗪𝗲𝗯𝗰𝗮𝘀𝘁 𝗔𝘁𝘁𝗲𝗻𝗱𝗲𝗲 𝗨𝗥𝗟
events.q4inc.com/attendee/79637…
𝗦𝗲𝗲 𝗙𝘂𝗹𝗹 𝗥𝗲𝗹𝗲𝗮𝘀𝗲: ir.ipatherapeutics.com/news/news-rele…
$HYFT #TechBio#Biotech#Ai#DrugDiscovery
𝗢𝗻𝗲 𝗯𝗿𝗮𝗻𝗱. 𝗘𝘅𝗽𝗼𝗻𝗲𝗻𝘁𝗶𝗮𝗹 𝗽𝗼𝘄𝗲𝗿 𝘁𝗼 𝘁𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺 𝗱𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆.
Earlier today, we announced our transition to MindWalk™ (NASDAQ: HYFT). The vision is now reality: one brand uniting technology, data and science to reshape discovery.
MindWalk brings together IPA, BioStrand, and Talem Therapeutics under one identity: a customizable biointelligence ecosystem engineered to solve the complex.
𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 𝗱𝗲𝗹𝗶𝘃𝗲𝗿𝘀:
• 𝗕𝗶𝗼-𝗻𝗮𝘁𝗶𝘃𝗲 𝗔𝗜 — LensAI™ powered by HYFT® technology, integrating 25B+ biologic connections to generate deeper insights, up to 3X faster
• 𝗔 𝗼𝗻𝗲-𝗼𝗳-𝗮-𝗸𝗶𝗻𝗱 𝗱𝗮𝘁𝗮 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺 — connecting sequence, structure, function, and literature to reveal hidden patterns
• 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗹𝗮𝗯 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 — with a demonstrated track record of supporting 15+ programs to the clinic and achieving >98% discovery success in our leading B cell technology
Patented. Validated. First-in-class. Together, we advance biologics discovery and development — providing deeper insight, greater scalability, and the potential for better patient outcomes.
𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲: 𝗺𝗶𝗻𝗱𝘄𝗮𝗹𝗸𝗔𝗜.𝗰𝗼𝗺
$IPA $HYFT #Biologics#IPA#BioStrand#Biotech#TechBio#DrugDiscovery#Antibodies
My fav misconception in the market is that people think they should be hitting bangers of 100% everyday because someone on social media did.
Well that person doesnt hit them everyday. Trust me. They may post the winners but they arent posting their losers.
Yes people hit bangers all the time. But the expecation to do it everyday is just nonsense.
𝗣𝗿𝗲𝘀𝘀-𝗥𝗲𝗹𝗲𝗮𝘀𝗲: 𝗔𝗜-𝗗𝗲𝘀𝗶𝗴𝗻𝗲𝗱 𝗚𝗟𝗣-𝟭 𝗣𝗲𝗽𝘁𝗶𝗱𝗲𝘀 𝗳𝗿𝗼𝗺 𝗜𝗺𝗺𝘂𝗻𝗼𝗣𝗿𝗲𝗰𝗶𝘀𝗲 𝗔𝗻𝘁𝗶𝗯𝗼𝗱𝗶𝗲𝘀 𝗦𝘂𝗿𝗽𝗮𝘀𝘀 𝗦𝗲𝗺𝗮𝗴𝗹𝘂𝘁𝗶𝗱𝗲 𝗶𝗻 𝗧𝗵𝗶𝗿𝗱 𝗣𝗮𝗿𝘁𝘆 𝗥𝗲𝗰𝗲𝗽𝘁𝗼𝗿 𝗔𝗰𝘁𝗶𝘃𝗮𝘁𝗶𝗼𝗻 𝗦𝘁𝘂𝗱𝗶𝗲𝘀
GLP-1 therapies are one of the fastest-growing areas in pharma—and these results mark two clear breakthroughs: two IPA AI-optimized peptides matched or outperformed Semaglutide in receptor activation assays. All five candidates were engineered for increased stability and resistance to peptidase degradation. The second breakthrough: AI proved its ability in designing peptide sequences advancing its role in therapeutic design. “This is not a one-off success. We’ve demonstrated a scalable, first-principles mechanism to design potent, stable, and biologically active peptide therapeutics. HYFT-guided design unlocks repeatable workflows for other validated targets—whether in cardiometabolic disease, oncology, or infectious disease." said Dr. Jennifer Bath, CEO of ImmunoPrecise.
𝗥𝗲𝗮𝗱 𝗳𝘂𝗹𝗹 𝗿𝗲𝗹𝗲𝗮𝘀𝗲 𝗳𝗼𝗿 𝗺𝗼𝗿𝗲 𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝘄𝗵𝗮𝘁 𝘁𝗵𝗲 𝗽𝗿𝗲𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗽𝗮𝘁𝗵 𝗶𝘀: bit.ly/3SNjloY
$IPA #GLP1#Semaglutide#AI#DrugDiscovery
The power outages in Spain and Portugal I fear were just a practice run and the cause more sinister than being reported. I really hope I am wrong! #poweroutage#Spain#Portugal#Blackout
Press release: FDA recent decision to phase out animal testing requirement—highlighting alignment of IPA's strategic direction.
The FDA’s announcement marks a significant advancement in regulatory modernization and aligns fully with ImmunoPrecise’s mission to revolutionize drug discovery and development processes through cutting-edge, human-relevant technologies, including its proprietary AI platform, LENSᵃⁱ™.
With our proprietary LENSᵃⁱ platform, and full suite of integrated discovery and development tools, we’re opening doors to drug development that are not only more efficient—but also potentially safer and data-driven from the start. From safety and toxicity prediction to immunogenicity screening and drug efficacy knowledge graphs, it’s intelligence engineered for therapeutic impact and aligned with the FDA’s New Approach Methodologies (NAMs) framework to support regulatory compliance.
See full release: ir.ipatherapeutics.com/news/news-rele…
$IPA#AIforHealth#Antibodies#AI#DrugDiscovery#Biotech#TechBio
Updated stat - Everyone likes to talk about homes prices in Canada. Here's an interesting stat. In 2004 a Big Mac in Canada cost you roughly $2.33 while the average Canadian home price was $245,149. Today a Big Mac will cost you $7.79 up 234% while the average home price was $703,446 in April up 187%. It would have cost you 105,214 Big Macs to buy a home in 2004 but now it would cost you 90,301 Big Macs and up from 85,129 Big Macs in December 2023.